Cedars-Sinai experts are advocating for patients to have access to GLP-1 medications such as semaglutide as a key component to caring for and preventing cardiovascular disease.
Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Jim Cramer in a latest program mentioned an analyst downgrade on The J. M. Smucker Company (NYSE:SJM) and reiterated that he ...
Doctors say that for many patients, these medications help them get control of their obesity and other weight-related medical issues, along with improving their blood sugar and heart health. However, ...
In this Saturday edition of BI Today, we're talking about the end of a GLP-1 shortage, and Hollywood's awards season.
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
“Jack of all trades” is a saying implying someone who has skills in different areas. The newer GLP-1 medications may qualify as such. The GLP-1s include semaglutide (Ozempic, Wegovy) and the ...
Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...
The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...
Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...
Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.